Regeneron Pharmaceuticals has rallied sharply into its July 29 earnings date, yet the Street's response has been to lower price targets rather than raise them — a divergence that frames the week's most interesting tension.
Options traders have shifted notably more bullish over the past six weeks. The put/call ratio has dropped to 0.77, well below its 20-day average of 0.83 and roughly 1.5 standard deviations below that mean. The move is particularly striking in context: as recently as late May the PCR was running above 1.05, reflecting meaningful downside hedging. That protective positioning has unwound steadily as the stock climbed, with call interest now clearly outpacing puts. The borrow market adds no countervailing signal. Availability is effectively unlimited — shares available for lending sit at a multiple far beyond any short-seller demand — and the cost to borrow at 0.52% is among the cheapest in the large-cap biotech universe. Short interest at 3.2% of free float is up 17% over the past month in share terms, but starting from such a modest base and against such frictionless availability, the build looks like portfolio hedging rather than a conviction short thesis.
The Street is directionally supportive but has spent the past two days walking back its ambitions. Morgan Stanley maintained its Equal-Weight rating on July 8 but cut the target from $788 to $730, landing just above the current price of $676. RBC Capital similarly trimmed from $707 to $696 while holding Sector Perform. Both moves sit close to or below the current trading level, signalling limited near-term conviction. Elsewhere the posture is more constructive: HSBC holds a Buy with a $880 target (cut from $990 on July 6), Cantor Fitzgerald kept Overweight at $750, and Truist Securities maintained Buy at $769. The consensus mean target of $822 implies roughly 22% upside from current levels, though the direction of travel on recent revisions is clearly downward. The bull case rests on Dupixent's continued label expansion, pipeline optionality in ophthalmology and oncology, and a forward earnings growth rank sitting at the 83rd percentile relative to peers. Bears point to biosimilar risk on Eylea, longer-term Dupixent exclusivity questions, and the modest EPS surprise track record — a 32nd-percentile ranking that signals the company has tended to land in line rather than beat.
The earnings reaction history is thin but worth noting. The last print on April 29 produced a 3.4% one-day decline and the stock was still down 1.5% five sessions later. The June 12 event — flagged in the data as a separate earnings date, though likely a conference presentation — resulted in a negligible 0.6% move. The next scheduled print is July 29. Close peer GILD added 7.9% on the week and VRTX gained 4.5%, making REGN's 8.5% rise broadly in line with a rising tide for large-cap biotech rather than a company-specific re-rating. BIIB bucked the trend, falling 5% — a reminder that the sector tailwind is not uniform.
The dividend score of 93 stands out as a quiet positive for longer-duration holders, and the days-to-cover rank of 75 suggests any short squeeze would have real teeth if sentiment shifted — but with availability this loose, that scenario requires a meaningful fundamental catalyst. The setup heading into July 29 is therefore less about whether positioning is extreme and more about whether the pipeline readouts expected in Q3 can justify a multiple that, at roughly 12.5x trailing earnings, already prices in considerable execution.
See the live data behind this article on ORTEX.
Open REGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
